X-group (possible homology)

5101 C-terminal helical domain of RNA helicase

Open in classification tree →

Ligands and drugs

222

Member domains

with ligand contacts (≤ 4 Å)

41.0% of members

with DrugDomain annotations

38.3% of members

with a DrugBank compound

23.9% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.

Proteins with classified ligands

Superclasses bound (of 23)

—

Superclasses per 20 proteins

fewer than 20 proteins: too few to compare at equal depth

The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.

Superclass	Proteins	Expected	Ratio	Significance
Organosulfur compounds	1	0.1	8.22×	not tested
Organoheterocyclic compounds	5	0.9	5.49×	not tested
Benzenoids	2	0.4	4.62×	not tested
Organic acids and derivatives	2	0.9	2.19×	not tested
Homogeneous non-metal compounds	1	1.3	0.79×	not tested
Homogeneous metal compounds	1	2.9	0.34×	not tested

enriched (q < 0.05)depleted (q < 0.05)not significantnot tested (expected < 5)

Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.

DrugBank compounds

No DrugBank compounds are annotated on this group's domains.

Most frequently bound compounds

PDB ligand	Name	Domains in contact
4VA	(2S)-4-amino-N-[(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propyl]-4-oxobutan-2-aminium	4
3VY	(1-methyl-1H-indol-3-yl)acetic acid	3
1LH	(2S)-4-[(2-ammonioethyl)amino]-N-[(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propyl]-4-oxobutan-2-aminium	2
20L	(4-phenoxyphenyl)methylazanium	2
3VZ	{6-(3,5-diaminophenyl)-1-[4-(propan-2-yl)benzyl]-1H-indol-3-yl}acetic acid	2
DJL	(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propan-1-aminium	2
F9K	(1'R,2R,2'S,6S,24AS)-17-FLUORO-6-(1-METHYL-2-OXOPIPERIDINE-3-CARBOXAMIDO)-19,19-DIOXIDO-5,21,24-TRIOXO-2'-VINYL-1,2,3,5,6,7,8,9,10,11,12,13,14,20,21,23,24,24A-OCTADECAHYDROSPIRO[BENZO[S]PYRROLO[2,1-G][1,2,5,8,18]THIATETRAAZACYCLOICOSINE-22,1'-CYCLOPRO-2-CARBOXYLATEPAN]-2-YL 4-FLUOROISOINDOLINE	2
PW1	[2,4-bis(fluoranyl)-3-phenoxy-phenyl]methylazanium	2
R2N	5-bromo-1-methyl-1H-indole-2-carboxylic acid	2
10L	1H-indazol-7-amine	1
2SX	(5-bromo-1H-indol-3-yl)acetic acid	1
2SY	[1-(3-chlorobenzyl)-1H-indol-3-yl]acetic acid	1
2T2	[1-(3-ethynylbenzyl)-1H-indol-3-yl]acetic acid	1
2T7	[1-(2-methoxy-5-nitrobenzyl)-1H-indol-3-yl]acetic acid	1
2T9	[6-(3,5-diaminophenyl)-1-(2-methoxy-5-nitrobenzyl)-1H-indol-3-yl]acetic acid	1
7ZC	1-(5-methoxy-1H-indol-3-yl)-N,N-dimethyl-methanamine	1
AWD	~{N}-(4-fluorophenyl)-4-methyl-piperazine-1-carboxamide	1
BME	BETA-MERCAPTOETHANOL	1
CAmetal	CALCIUM ION	1
CL	CHLORIDE ION	1